	Srodki Pieniężne I Ekwiwalent		Data
Acadia Pharmaceuticals	USD 847.02M	85.02M	2025-09
Agios Pharmaceuticals	USD 92.71M	11.84M	2025-09
Akebia Therapeutics	USD 166.44M	29.14M	2025-09
Alnylam Pharmaceuticals	USD 1.49B	376.56M	2025-09
Amarin	USD 122.8M	25.08M	2025-09
Ardelyx	USD 42.72M	47.32M	2025-09
Astellas Pharma	JPY 188.37B	8.51B	2025-03
AstraZeneca	USD 8.14B	1.08B	2025-09
Charles River Laboratories	USD 207.1M	24.27M	2025-09
Coherus Biosciences	USD 103.35M	113.54M	2025-09
Esperion Therapeutics	USD 92.45M	6.39M	2025-09
Exact Sciences	USD 789.04M	131.94M	2025-09
Halozyme Therapeutics	USD 419.66M	357.8M	2025-09
Incyte	USD 3.58B	650.78M	2025-12
Ironwood Pharmaceuticals	USD 140.41M	47.56M	2025-09
Karyopharm Therapeutics	USD 37.67M	1.05M	2025-09
Lexicon Pharmaceuticals	USD 21.36M	41.52M	2025-06
MacroGenics	USD 80.13M	50.56M	2025-09
Moderna	USD 1.13B	147M	2025-09
Myriad Genetics	USD 145.4M	71M	2025-09
Pacira	USD 147.59M	152.89M	2025-09
PTC Therapeutics	USD 672.62M	344.77M	2025-09
Puma Biotechnology	USD 53.52M	1.14M	2025-09
Sarepta Therapeutics	USD 613.08M	102.48M	2025-09
Takeda	JPY 654.94B	26.55B	2025-12
Ultragenyx Pharmaceutical	USD 202.51M	36.4M	2025-09
Vanda Pharmaceuticals	USD 70.02M	10.96M	2025-09

Ironwood Pharmaceuticals Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Feb 2026.